[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574486":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":30,"collaborators":20,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":20,"eligibilityCriteria":40,"healthyVolunteers":41,"sex":42,"minAge":20,"maxAge":20,"enrollmentInfo":43,"targetDuration":20,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":56,"whyStopped":20,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":20},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflizon in Atrial fibrillation on Rythme control","ACTIVE_COMPARATOR","investigator study the efficacy and safety outcomes of Dapagliflozin use among newly diagnosed AF patients when underwent rhythm control strategy regardless their diabetic status.\n\nAfter enrollment, the patients will be treated with dapagliflozin (10 mg\u002Fd) or placebo at the time of rhythm control strategy and will continue daily treatment at the same dose till the 9 month follow-up period.",[13],"Drug: Dapagliflozin (DAPA)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Dapagliflozin (DAPA)","We will record all baseline characteristics (Age, sex, BMI, HR and BP), AF type, EHRA class, previous use of ADD (B blockers, Class I, III AAD), previous CV, prior cerebrovascular stroke and Co-morbidities (HTN, DM, IHD, HF, Renal impairment, peripheral arterial disease, OSAS). CHADS2Vasc score and HAS-BLEED score will be calculated. Trans-thoracic echocardiograms will be performed within 4 weeks before the rhythm control attempts to determine LA diameter and volumes and left ventricular hypertrophy and functions (EF and E\u002F'e).\n\nAfter enrollment, the patients will be treated with dapagliflozin (10 mg\u002Fd) or placebo at the time of rhythm control strategy and will continue daily treatment at the same dose till the 9 month follow-up period.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Hanan Gamal, master student","CONTACT","+20 1013751813","hanangamal314@gmail.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":20},"salah Ata, cardiologist","+20 1091318801",{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Hanan Gamal","resident physician of cardiology","100574486","phase-1-dapagliflozin-on-outcomes-of-rhythm-control-strategy-pharmacological--interventional-in-patient-with-atrial-fibrillation-100574486",false,"NCT06759909","Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation","Influence of Use of Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation","Inclusion Criteria:\n\n* Newly diagnosed AF patients (Time between AF diagnosis to rhythm control attempt less than one year) Paroxysmal and persistent atrial fibrillation (AF) documented on a 12 lead ECG, Holter monitor (episodes of AF must be \\>30 seconds in duration to qualify as an inclusion criterion) Age of 18 years or older on the date of consent. Informed Consent\n\nExclusion Criteria:\n\n* Long standing persistent AF. Previous use of dapagliflozin within one month of rhythm control attempt. Previous rhythm control attempt. AF due to reversible cause (e.g. hyperthyroidism, cardiothoracic surgery). History of congestive heart failure. Active intracardiac thrombus Pre-existing pulmonary vein stenosis or pulmonary vein stent Contraindication to anticoagulation or radio contrast materials",true,"ALL",{"count":44,"type":45},100,"ESTIMATED","INTERVENTIONAL",[48],"PHASE1","Investigator study the efficacy and safety outcomes of Dapagliflozin use among newly diagnosed Atrial fibrillation patients when underwent rhythm control strategy regardless their diabetic status.",[51,52],"Dapagliflozin (Forxiga)","Atrial Fibrillation (AF)",[54,55],"dapagliflozin","rythme control","NOT_YET_RECRUITING","2025-01-03",{"date":59,"type":60},"2025-01-06","ACTUAL",{"date":57,"type":45},{"date":63,"type":45},"2028-12-22",{"name":5,"class":6}]